Perspectives and Future Directions in Biosimilar Health Care Delivery
A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program implementation challenges across different care settings and emphasizing the importance of robust operational frameworks.
Video content above is prompted by the following:
- What would you like your payer colleagues to know about the use of biosimilars in the health system?
- What would you like to share with colleagues who might be starting or growing their biosimilar program?
- Please describe the differences in health care provider–administered vs retail settings with the use of biosimilars.
- What additional thoughts would you like to share on operationalizing biosimilars?
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
